Hous­ton biotech Ar­a­vive re­ports PhI­II ovar­i­an can­cer fail, shares nose­dive

A small Hous­ton start­up re­port­ed a Phase III fail for an ovar­i­an can­cer drug Wednes­day af­ter­noon, send­ing its share price plum­met­ing.

Ar­a­vive said Wednes­day that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER